Publications by authors named "David Cahall"

Claim this Profile
R
Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study.
Richard Eastell, Patrick Garnero, Christine Audebert, David L Cahall

Bone· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.
Richard Eastell, Bernard Vrijens, David L Cahall, Johann D Ringe, Patrick Garnero

J Bone Miner Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
René Rizzoli, Nansa Burlet, David Cahall, Pierre D Delmas, Erik Fink Eriksen

Bone· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Artur J Racewicz, Pamela J Schofield, David L Cahall, Gary A Cline, David E Burgio

Curr Med Res Opin· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
Pierre D Delmas, Bernard Vrijens, Richard Eastell, Christian Roux, Huibert A P Pols, David Cahall

J Clin Endocrinol Metab· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study.
Pierre D Delmas, Lex van de Langerijt, Nelson B Watts, Richard Eastell, Harry Genant, David L Cahall

J Bone Miner Res· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis